I would agree with you that data by itself might cause a small but temporary bump but at this point it would have to be accompanied with actual news that some pharma or pharmas are actually going to use the test and that Amarantus will actually start to make money off of Lympro. At some point the rhetoric actually has to materialize for the stock to move in the right direction.